Media and Communications

News

2000 News Releases

Friday, December 29, 2000
Israel Makov Appointed COO

Jerusalem, December 29, 2000 - Jerusalem, Israel, December 29, 2000, Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced the appointment of Israel Makov as Chief Operating Officer. Mr. Makov, who most recently served as Executive Vice President, was responsible for global business development and contributed to Teva's global growth through a strategy of mergers and acquisitions. During his tenure, Teva has developed a global organizational structure and has become the leading generic pharmaceutical company in the world. The appointment of Mr. Makov will enable Eli Hurvitz, Teva's Read More »

Tuesday, December 05, 2000
Teva Launches Copaxone® in the U.K.

Jerusalem, Israel, December 5, 2000 - Teva Pharmaceutical Industries, Ltd., (Nasdaq: TEVA) announced today that Copaxone® was launched in the U.K., the product's first major European market. Copaxone® (glatiramer acetate for injection) is indicated for reduction in frequency of relapses in relapsing-remitting multiple sclerosis (RR-MS). There are approximately 85,000 patients in the U.K of which 30,000 are RR-MS patients.Copaxone® will be jointly marketed in the U.K. by Teva and Aventis.Peter Cardy, Chief Executive of the U.K. MS Society said: "The MS Society welcomes the availability of Read More »

Tuesday, December 05, 2000
Teva Received Final Approval for Nifedipine CC 60mg and will Launch Immediately

180-DAY EXCLUSIVITY Jerusalem, Israel, December 5, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the receipt from the U.S. FDA of final approval to manufacture and market Nifedipine CC 60 mg Tablets. Nifedipine CC is the generic version of Bayer's hypertension drug - Adalat CC®. 1999 branded sales of the 60 mg strength were approximately $200 million. This approval was issued to Biovail Corporation. The product is included in the exclusive US marketing agreement between Teva and Biovail relating to Biovail's line of generic sustained release products. Biovail was t Read More »

Tuesday, November 07, 2000
Teva Earnings per share for Q3 2000 rise 26% Copaxone sales rise 59%

Consolidated Statements of IncomeBalance Sheet DataSales for the Quarter ended September 30Jerusalem, Israel, November 7, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported that Net income for the third quarter 2000 reached $46.6 million or $0.36 per share, up 29% and 26% respectively as compared with the third quarter of 1999 (before a one-time charge in respect of acquired in-process R&D in the comparable quarter). The geographic breakdown of third quarter Total sales of $450.1 million (+40%) is: North America 59%, Europe 22%, Israel 14% and others 5%. Eli Hurvitz, Read More »

Sunday, October 22, 2000
Teva Received Final Approval for Doxazosin Mesylate

TO BE SHIPPED IMMEDIATELY Jerusalem, Israel, October 22, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has received from the U.S. FDA final approval to manufacture and market Doxazosin Mesylate 1, 2, 4 and 8 mg Tablets.Doxazosin Mesylate is the generic version of Pfizer's cardiovascular/benign prostatic hyperplasia drug - Cardura®. Combined 1999 branded sales were approximately $320 million. Teva received the final approval upon the expiration of the patent on the branded product and will ship the product immediately. Other companies have received similar a Read More »

Thursday, October 12, 2000
Teva Announces Pricing of Convertible Debenture Offering

Jerusalem, Israel, October 12, 2000 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that Teva Pharmaceutical Finance, LLC ("Teva Finance"), a special purpose U.S. finance subsidiary of Teva, priced its offering of $500 million in aggregate principal amount of 1.5% Convertible Senior Debentures due 2005. The debentures will be convertible into American Depositary Receipts of Teva at the conversion price of U.S. $ 86.23 per ADR (reflecting a premium of 26%, relative to the Nasdaq closing price for Teva's ADRs of U.S. $ 68.4375 on October 4, 2000). The Debentures Read More »

Thursday, September 28, 2000
Teva Announces Final Approval of Nifedipine XL 60 mg and will Launched Imminently

180-DAY EXCLUSIVITY Jerusalem, Israel, September 28, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the FDA awarded final U.S. approval for Nifedipine XL 60mg. This approval was issued to Biovail Corporation. The product is included in the exclusive US marketing agreement between Teva and Biovail relating to Biovail's line of generic sustained release products. Nifedipine XL is the generic version of Pfizer's drug Procardia XL® for the treatment of hypertension and angina. In 1999, U.S. sales of this product were approximately $230 million.Biovail was the first Read More »

Friday, September 22, 2000
Teva Announces Proposed Offering of Convertible Debentures in a Rule 144a Offering

Jerusalem, Israel, September 22, 2000 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that, subject to market and other conditions and the approval of its Board of Directors, it intends to offer approximately $300 million of five year Convertible Senior Debentures of a special purpose U.S. finance subsidiary. The debentures are expected to be guaranteed by Teva and to be convertible into American Depositary Receipts of Teva. The offering will be made by means of an offering memorandum to qualified institutional buyers pursuant to Rule 144A and to certain persons in offs Read More »

Tuesday, September 19, 2000
Teva Receives First Generic Approval for Amoxicillin 500 and 875 mg Tablets

Jerusalem, Israel, September 19, 2000 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has received from the U.S. FDA final approval to manufacture and market Amoxicillin 500 and 875 mg Tablets, intended for twice-daily dosage.Amoxicillin is the generic version of SmithKline Beecham’s Amoxil, for the treatment of infections due to susceptible organisms. Sales of these strengths of the branded product in the U.S. were approximately $34 million in 1999.Teva’s application was the first approval for a generic version of these strengths of Amoxil. Teva intends to launch Read More »

Thursday, September 07, 2000
the Israeli Supreme Court Fully Acquitted Eli Hurvitz, Teva's President and CEO

JERUSALEM, Israel, September 7, 2000 - Teva Pharmaceutical Industries, Ltd., (Nasdaq: TEVA) announced today that the Israeli Supreme Court acquitted Eli Hurvitz from all charges relating to tax avoidance by Promedico.Throughout the entire trial and appeal the Board of Directors has had faith and full confidence in Mr. Hurvitz's innocence and integrity and therefore requested Eli Hurvitz to continue his leadership as he has done for more than 20 years as Teva's President and CEO, for the benefit of the company and its shareholders."Under Eli Hurvitz's leadership, Teva has established itsel Read More »

​​​